Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy-Reference-Cited by-同舟云学术

Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy

Published:2010-07-04 Issue:8 Volume:42 Page:715-721
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Barretina Jordi,Taylor Barry S,Banerji Shantanu,Ramos Alexis H,Lagos-Quintana Mariana,DeCarolis Penelope L,Shah Kinjal,Socci Nicholas D,Weir Barbara A,Ho Alan,Chiang Derek Y,Reva Boris,Mermel Craig H,Getz Gad,Antipin Yevgenyi,Beroukhim Rameen,Major John E,Hatton Charles,Nicoletti Richard,Hanna Megan,Sharpe Ted,Fennell Tim J,Cibulskis Kristian,Onofrio Robert C,Saito Tsuyoshi,Shukla Neerav,Lau Christopher,Nelander Sven,Silver Serena J,Sougnez Carrie,Viale Agnes,Winckler Wendy,Maki Robert G,Garraway Levi A,Lash Alex,Greulich Heidi,Root David E,Sellers William R,Schwartz Gary K,Antonescu Cristina R,Lander Eric S,Varmus Harold E,Ladanyi Marc,Sander Chris,Meyerson Matthew,Singer Samuel

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.619.pdf

Reference54 articles.

1. Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

2. Fletcher, C., Unni, K. & Mertens, F. (eds.) Pathology and Genetics of Tumors of Soft Tissue and Bone 427 (International Agency for Research on Cancer Press, Lyon, France, 2002).

3. Heinrich, M.C. et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299, 708–710 (2003).

4. Hirota, S. et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279, 577–580 (1998).

5. Demetri, G.D. et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347, 472–480 (2002).

Cited by 612 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Atypical Spindle Cell/Pleomorphic Lipomatous Tumor: A Review and Update;Cancers;2024-09-13

2. A multimodal neural network with gradient blending improves predictions of survival and metastasis in sarcoma;npj Precision Oncology;2024-09-05

3. Molecular characteristics and systemic treatment options of liposarcoma: A systematic review;Biomedicine & Pharmacotherapy;2024-09

4. A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors;ESMO Open;2024-08

5. Successful pazopanib treatment of undifferentiated pleomorphic sarcoma with coamplification of PDGFRA, VEGFR2 and KIT: A case report;Molecular and Clinical Oncology;2024-07-29